Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder

Autism Spectrum Disorder Clinical Trial

Official title:

Intranasal Ketamine Use in Autism Spectrum Disorder: A Placebo-Controlled Crossover Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02611921
• Other study ID #: 2015-2494
• Status: Completed
• Phase: Phase 1
• Start date: December 22, 2015
• Est. completion date: May 7, 2018

Study information

• Verified date: October 2018
• Source: Children's Hospital Medical Center, Cincinnati
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to determine if intranasal ketamine shows initial evidence of safety, tolerability and efficacy for the treatment of social impairment in individuals with Autism Spectrum Disorder.

Description:

To address the significant need for effective treatment of core symptoms of Autism Spectrum Disorder (ASD), this trial is designed as a double-blind, placebo-controlled crossover pilot study of intranasal ketamine in 24 individuals with ASD ages 12- 30 years using a novel quantitative eye-tracking outcome measure to assess impact of the drug on social impairment. Additionally, to develop a ketamine-focused personalized medicine approach in ASD, the investigators will include pharmacokinetic, molecular pharmacodynamic, and electrophysiological assessments into initial systematic study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: May 7, 2018
• Est. primary completion date: May 7, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 30 Years

Eligibility

Inclusion Criteria:

• Ages 12 to 30 years old.

• Weight equal to or greater than 50 kg.

• General good health as determined by physical exam, medical history, laboratory work up, and EKG.

• Diagnostic and Statistical Manual of Mental Disorders 5th Edition diagnosis of autism spectrum disorder (not associated with Fragile X Syndrome or other known genetic syndrome) as confirmed by the Autism Diagnostic Observation Schedule at screen or previous (within last 5 years) if available.

• Valid Intelligence Quotient (IQ) score greater than or equal to 50 as confirmed via testing (Leiter-3) at screen or previous (within last 5 years, any valid testing acceptable).

• Clinical Global Impressions-Severity score of 4 (Moderately Ill).

• Score of 10 on the Social Withdrawal subscale of the Aberrant Behavior Checklist.

• Stable dosing of all concomitant psychotropic medications for five half-lives prior to screening visit and during the study.

• Presence of parent/guardian or significant other or caregiver willing to serve as informant for behavioral outcome measures.

Exclusion Criteria:

• Presence of co-morbid schizophrenia, schizoaffective disorder, bipolar disorder with psychosis, bipolar disorder or psychosis not otherwise specified. Comorbid diagnoses determined by psychiatrist clinical interview and use of Diagnostic and Statistical Manual of Mental Disorders 5th Edition diagnostic criteria.

• History of drug or alcohol abuse.

• Presence of cardiac disease including coronary artery disease, congestive heart failure, or uncontrolled hypertension per medical history (individuals with = 2 blood pressure readings of =140/90 during screen/baseline will be excluded).

• Airway instability, tracheal surgery, or tracheal stenosis per medical history.

• Central nervous system masses or hydrocephalus per medical history.

• Porphyria, thyroid disorder, or thyroid medication use per medical history.

• Glaucoma or other cause of increased intraocular pressure per medical history.

• Allergy to ketamine.

• Current use of drugs with concomitant modification of non-competitive N-methyl-D-aspartate glutamate activity (acamprosate, amantadine, memantine, d-cycloserine etc.)

• For female subjects of child bearing potential, a positive pregnancy test.

• Any major chronic medical or chronic respiratory illness considered to be uncontrolled by the Principal Investigator.

• Inability to tolerate study procedures or study drug per the discretion of the Principal Investigator.

Related Conditions & MeSH terms

• Autism Spectrum Disorder
• Autistic Disorder
• Child Development Disorders, Pervasive
• Disease

Intervention

Drug:
• Ketamine
Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator
• Placebo
Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator

Locations

Country	Name	City	State
United States	Cincinnati Childrens Hospital Medical Center	Cincinnati	Ohio

Sponsors (3)

Lead Sponsor	Collaborator
Children's Hospital Medical Center, Cincinnati	Cures Within Reach, Roivant Sciences, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Social Withdrawal subscale score of the Aberrant Behavior Checklist (ABC)	The ABC is the gold standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials.	Social withdrawal subscale change from baseline to final visit on day 35 ± 2 days
Secondary	Change in the Clinician-rated CGI Improvement scale (CGI-I)	The CGI-I is a 7-point scale designed to measure symptomatic change at a specific time as compared to baseline. The CGI-I will be focused on the target symptoms of social impairment. CGI-I is a gold standard measure of potential change with treatment in placebo- controlled pharmacotherapy trials in ASD	CGI-I change from baseline to final visit on day 35 ± 2 days